Pharmacopoeia

Global Biopharmaceutical Excipient Manufacturing Market to 2035 - by Type of Biologics, Type of Excipient, Scale of Operation and Key Geographies - ResearchAndMarkets.com

Retrieved on: 
Montag, März 21, 2022
Biotechnology, Pharmaceutical, Health, Lipid, Food Chemicals Codex, Lactose, Therapy, Polymer, Peptide, API, Organic acid, Polysorbate 20, Excipient, Vaccine, American Chemical Society, Antioxidant, Mannitol, Salt, Solubility, Industry, Safety, Benzyl alcohol, Protein, Trehalose, PH, Pharmacopoeia, A-DNA, COVID-19, US, GMP, Carbohydrate, Partnership, Antibody, Fine chemical, Generic drug, British Pharmacopoeia, Indian Pharmacopoeia Commission, Japanese Pharmacopoeia, European Pharmacopoeia

Therefore, a variety of excipients, which are pharmacologically inert substances themselves, are used to stabilize biologics during the manufacturing process and storage.

Key Points: 
  • Therefore, a variety of excipients, which are pharmacologically inert substances themselves, are used to stabilize biologics during the manufacturing process and storage.
  • Considering the technical and routine operations-related challenges, an increasing number of biologics developers are increasingly relying on biopharmaceutical excipient manufacturers.
  • Which global regions are considered as key hubs for biopharmaceutical excipient manufacturing?
  • How is the current and future market opportunity likely to be distributed across key market segments?

CDK9 Inhibitor Pipeline Market Report 2022: Insights About 15+ Companies and 15+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Montag, Januar 31, 2022
Health, Pharmaceutical, Alvocidib, Merck & Co., Acute myeloid leukemia, III, CDK5, Cyclin T1, CTD, KDA, RNA polymerase II, Clinical trial, CDK, Discovery, Neoplasm, Cyclin-dependent kinase 9, Gene expression, ATP, II, Cancer, Cell cycle, Ligand Pharmaceuticals, SCH, Gene, Protein kinase, MYC, Pharmacopoeia, News, CDK2, Blockade, CDK9, Therapy, Association, Schering-Plough, RNA, Chronic lymphocytic leukemia, CDK1, Fertilizer, Vaccine, Pharmaceutical industry

This "Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cyclin-Dependent Kinase 9 (CDK9) Inhibitor pipeline landscape.

Key Points: 
  • This "Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cyclin-Dependent Kinase 9 (CDK9) Inhibitor pipeline landscape.
  • There are 2 isoforms of the CDK9 protein: the major 42 kDa CDK9 isoform, and the minor 55 kDa isoform.
  • 15+ key companies which are developing the Cyclin-Dependent Kinase 9 (CDK9) Inhibitor.
  • The companies which have their Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drug candidates in the most advanced stage, i.e.

Universe Pharmaceuticals INC Announces Strategic Alliance with Jiangxi Province Institute of Materia Medica to Conduct Research on Traditional Chinese Medicine

Retrieved on: 
Dienstag, Januar 4, 2022
Universe, People, Particle-size distribution, INC, Dietary supplement, Compliance, Republic, GLOBE, Company, SEC, CEO, UPC, Ageing, Research, Marketing, Review, Nasdaq, Agreement, Pharmacopoeia, Phrase, Astragalus, Pharmaceutical industry, Medicinal plants, Materia medica, Epimedium

As part of the Agreements, both parties agreed to collaborate on scientific research, talents development, and project collaboration to further create formulas for traditional Chinese medicine.

Key Points: 
  • As part of the Agreements, both parties agreed to collaborate on scientific research, talents development, and project collaboration to further create formulas for traditional Chinese medicine.
  • Gang Lai, Chairman and CEO of Universe Pharmaceuticals INC, commented, We are excited to partner with Jiangxi IMM.
  • Affiliated to the Jiangxi Province Medical Products Administration, Jiangxi Province Institute of Materia Medica was established in 1973.
  • The Company also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies.

Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds

Retrieved on: 
Freitag, September 10, 2021

Mr Morris will be advising COMPASS on research related to new psychedelic compounds that could be developed into therapies in areas of unmet mental health need.

Key Points: 
  • Mr Morris will be advising COMPASS on research related to new psychedelic compounds that could be developed into therapies in areas of unmet mental health need.
  • Mr Morris said: For over a decade, Jason and I have worked together studying the chemistry and pharmacology of psychedelics.
  • Lars Wilde, Chief Business Officer, President and Co-founder, COMPASS Pathways, said, I am delighted to welcome Hamilton to our team.
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

Cantourage brings the first medical cannabis flowers from Jamaica to the European market via its Fast Track Access Platform

Retrieved on: 
Donnerstag, August 19, 2021
Good, Good manufacturing practice, Farm, Lumir, Research, Pharmacy, Darkness, Health, Pharmacopoeia, Multimedia, Patient, Partnership, Dronabinol, Light, GMP, Drug

Cannim will sell its products in the EU medical markets through the Cantourage Fast Track Access Platform.

Key Points: 
  • Cannim will sell its products in the EU medical markets through the Cantourage Fast Track Access Platform.
  • The agreement allows medical cannabis flowers from Jamaica to be made available to German patients for the first time.
  • Philip Schetter, Co-CEO of Cantourage comments: "We are delighted to offer patients in Germany this unprecedented opportunity by bringing medical cannabis from Jamaica into the fast-growing European medical cannabis market for the first time.
  • After the introduction of medical cannabis from Uruguay, Cannim's Jamaican Lumir is the second medical cannabis product entering the European market through the Fast Track Access Platform.

Cantourage brings the first medical cannabis flowers from Jamaica to the European market via its Fast Track Access Platform

Retrieved on: 
Donnerstag, August 19, 2021
Good, Good manufacturing practice, Farm, Lumir, Research, Pharmacy, Darkness, Health, Pharmacopoeia, Patient, Partnership, Dronabinol, Light, GMP, Drug

BERLIN, Aug. 19, 2021 /PRNewswire/ -- Cantourage, one of Europe's leading providers of medical cannabis, has today launched its offering of high-quality medical cannabis flowers from Jamaica in Germany. Cantourage has successfully partnered with Australian-based Cannim, the leading cultivator of medicinal cannabis in Jamaica. Cannim will sell its products in the EU medical markets through the Cantourage Fast Track Access Platform. The agreement allows medical cannabis flowers from Jamaica to be made available to German patients for the first time.

Key Points: 
  • Cannim will sell its products in the EU medical markets through the Cantourage Fast Track Access Platform.
  • The agreement allows medical cannabis flowers from Jamaica to be made available to German patients for the first time.
  • Philip Schetter, Co-CEO of Cantourage comments: "We are delighted to offer patients in Germany this unprecedented opportunity by bringing medical cannabis from Jamaica into the fast-growing European medical cannabis market for the first time.
  • After the introduction of medical cannabis from Uruguay, Cannim's Jamaican Lumir is the second medical cannabis product entering the European market through the Fast Track Access Platform.

Tryp Therapeutics Appoints Dennis Langer, M.D., J.D. as Senior Advisor

Retrieved on: 
Mittwoch, August 18, 2021
Psilocybin, Company, Columbia University, Research and development, University, CSE, Fibromyalgia, Whitehead Institute, Association for Molecular Pathology v. Myriad Genetics, Inc., THIS, Genetics, Risk, Georgetown University School of Dentistry, Therapy, Eating disorder, Georgetown University School of Medicine, Lists of diseases, Senior, Biotechnology, Senior advisor, Sirna Therapeutics, Chronic pain, News, GlaxoSmithKline, CEO, THE, Pharmacopoeia, Phrase, Harvard Law School, Biomedical Research, Drug development, Pharmaceutical industry, Risk management

San Diego, California--(Newsfile Corp. - August 18, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the appointment of Dennis Langer, M.D., J.D., as Senior Advisor to the Company.

Key Points: 
  • San Diego, California--(Newsfile Corp. - August 18, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the appointment of Dennis Langer, M.D., J.D., as Senior Advisor to the Company.
  • Dr. Langer previously served as a Director at several biotechnology companies that were successfully acquired including Pharmacopeia, Cytogen, Sirna Therapeutics, and Transkaryotic Therapies.
  • "I am looking forward to advising Tryp Therapeutics as they near the initiation of Phase 2a clinical trials this year," said Dr. Langer.
  • Commenting on the appointment, Greg McKee, Chairman and Chief Executive Officer of Tryp Therapeutics, said, "I am thrilled to welcome Dr. Langer as a Senior Advisor.

Meeting Pharmacopeia Regulations & Controlling the Risk of Contamination in Pharmaceutical Waters, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Mittwoch, November 25, 2020
Pharmacopoeia, USP, Pharmaceutical industry

TORONTO, Nov. 25, 2020 /PRNewswire-PRWeb/ --This webinar will cover key analytical requirements and regulations to ensure pharmacopeia compliance of pharmaceutical waters.

Key Points: 
  • TORONTO, Nov. 25, 2020 /PRNewswire-PRWeb/ --This webinar will cover key analytical requirements and regulations to ensure pharmacopeia compliance of pharmaceutical waters.
  • This will lead into a discussion on how the USP is harmonized with other global pharmacopeias, including European Pharmacopeia (EP), Japanese Pharmacopeia (JP), Chinese Pharmacopeia (ChP) and Indian Pharmacopeia (IP).
  • The speaker will then move into three specific analytics for pharmaceutical waters and the related measurement to help ensure pharmacopeia compliance of pharmaceutical waters.
  • For more information, or to register for this event, visit Meeting Pharmacopeia Regulations & Controlling the Risk of Contamination in Pharmaceutical Waters.

Metrohm USA and USP Team Up On USP Monograph Modernization Webinar

Retrieved on: 
Samstag, März 31, 2018
Rockville, Maryland, United States Pharmacopeia, USP, Metrohm, Pharmacopoeia, Unique selling proposition, Ion chromatography, Business economics, Economy, Business

Dr. Leonel Santos, Director of Chemical Medicines at USP, will provide an overview of the USP monograph modernization program. Dr. Michael Chang, Scientific Liaison Officer, will present an example of a successful modernization project where over-the-counter (OTC) products were analyzed for the quantification of zinc (USP 591) with selective Ion Chromatography (IC) methods.

Key Points: 
  • Metrohm USA is proud to partner with the United States Pharmacopeia (USP) and host a webinar describing the USP monograph modernization program and the impact of this program for analytical instruments in pharmaceutical laboratories.
  • Many USP monographs are decades old and do not reflect recent innovations and technology updates.
  • Metrohm USA invites scientists to attend this educational webinar where Dr. Leonel Santos, Director of Chemical Medicines at USP, will provide an overview of the USP monograph modernization program.
  • Metrohm USA is Metrohms largest subsidiary, employing more than 250 people across North America.